Deutsche Bank Aktiengesellschaft Has Lowered Expectations for Albemarle (NYSE:ALB) Stock Price

Albemarle (NYSE:ALB) had its price target decreased by Deutsche Bank Aktiengesellschaft from $109.00 to $105.00 in a research report report published on Wednesday.

Several other research analysts have also recently issued reports on ALB. Oppenheimer decreased their price objective on shares of Albemarle from $171.00 to $170.00 and set an “outperform” rating for the company in a report on Friday, November 8th. Robert W. Baird increased their price objective on shares of Albemarle from $79.00 to $103.00 and gave the company a “neutral” rating in a report on Wednesday, December 18th. Mizuho decreased their price objective on shares of Albemarle from $110.00 to $105.00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. Citigroup decreased their price objective on shares of Albemarle from $115.00 to $85.00 and set a “neutral” rating for the company in a report on Wednesday. Finally, Truist Financial assumed coverage on shares of Albemarle in a report on Tuesday, January 28th. They issued a “hold” rating and a $96.00 price objective for the company. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Albemarle presently has an average rating of “Hold” and a consensus target price of $112.38.

Albemarle Stock Performance

ALB stock opened at $81.20 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.58 and a current ratio of 2.44. The stock has a market capitalization of $9.54 billion, a price-to-earnings ratio of -4.85, a PEG ratio of 3.43 and a beta of 1.59. Albemarle has a 1 year low of $71.97 and a 1 year high of $143.19. The stock’s fifty day moving average is $89.09 and its two-hundred day moving average is $92.32.

Albemarle (NYSE:ALB) last issued its quarterly earnings data on Wednesday, February 12th. The specialty chemicals company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.49). Albemarle had a negative net margin of 28.80% and a positive return on equity of 1.67%. On average, research analysts predict that Albemarle will post -1.55 EPS for the current year.

Insider Activity at Albemarle

In related news, CEO J Kent Masters sold 2,525 shares of the company’s stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $101.12, for a total value of $255,328.00. Following the completion of the sale, the chief executive officer now owns 73,747 shares in the company, valued at approximately $7,457,296.64. This represents a 3.31 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.38% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Albemarle by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 14,594,499 shares of the specialty chemicals company’s stock valued at $1,256,294,000 after buying an additional 359,014 shares during the period. Primecap Management Co. CA increased its stake in shares of Albemarle by 0.5% during the 3rd quarter. Primecap Management Co. CA now owns 3,833,984 shares of the specialty chemicals company’s stock worth $363,117,000 after purchasing an additional 20,930 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Albemarle by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 2,795,891 shares of the specialty chemicals company’s stock worth $240,044,000 after purchasing an additional 53,985 shares during the last quarter. Earnest Partners LLC increased its stake in shares of Albemarle by 0.6% during the 4th quarter. Earnest Partners LLC now owns 1,432,153 shares of the specialty chemicals company’s stock worth $123,280,000 after purchasing an additional 8,243 shares during the last quarter. Finally, Northern Trust Corp increased its stake in shares of Albemarle by 12.1% during the 4th quarter. Northern Trust Corp now owns 1,290,797 shares of the specialty chemicals company’s stock worth $111,112,000 after purchasing an additional 139,600 shares during the last quarter. Institutional investors and hedge funds own 92.87% of the company’s stock.

Albemarle Company Profile

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services.